Lv4
526 积分 2021-09-06 加入
Minimal RB-responsive E1A Promoter Modification to Attain Potency, Selectivity, and Transgene-arming Capacity in Oncolytic Adenoviruses
11天前
已完结
A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses
11天前
已完结
Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11
11天前
已完结
Intravesical Infusion of Oncolytic Virus CG0070 in the Treatment of Bladder Cancer
24天前
已完结
CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor–Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer
24天前
已完结
Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial
24天前
已完结
Re: Oncolytic Immunotherapy with Nivolumab in Muscle-invasive Bladder Cancer: A Phase 1b Trial
24天前
已关闭
A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer
24天前
已完结
An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim results
24天前
已完结
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial
24天前
已完结
皖公网安备34019202002308